Among the various current therapeutic options, the long-acting GLP-1R agonist semaglutide and the GLP-1R/GIPR agonist tirzepatide are considered the most efficacious treatments for obesity and T2DM today due to their ability to both normalize glycemia and reduce food intake and body weight [see (1–3) for review]. This evidence concerns the gene GIPR and type 2 diabetes mellitus.